

PATENT
ATTORNEY DOCKET NO.: 029318/0404

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

40399/321/NIHD

In re patent application of

Jeffrey RUBIN *et al.*

Serial No. 08/477,983

Group Art Unit: 1646

Filed: June 7, 1995

Examiner: Saoud

For: AN EPITHELIAL CELL SPECIFIC
GROWTH FACTOR KERATINOCYTE
GROWTH FACTOR (KGF)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL

Transmitted herewith is an Amendment in the above-captioned application. The fee has been calculated as shown below. (*Small entity fees indicated in parentheses.*)


CLAIMS AS AMENDED						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee
Total Claims <i>(Small Entity)</i>	34	-	27	7	18.00	\$126.00
Independent claims <i>(Small Entity)</i>	2	-	3	0	78.00	.00
Multiple Dependent <i>(Small Entity)</i>	0		0	0	260.00	.00
Total						\$126.00

98 NOV 20 AM 11:37
TECH CENTER 1600/2900
RECEIVED

ATTORNEY DOCKET NO.: 040399/0321
APPLN. NO.: 08/477983

No fee is believed to be due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 19-0741.

Respectfully submitted,



Patricia D. Granados
Patricia D. Granados
Reg. No. 33,683

Dated: November 20, 1998

Foley & Lardner
Washington Harbour
3000 K Street, N.W.
Washington, D.C. 20007
Phone: (202) 672-5538
Fax: (202) 672-5399

#21G
G.S.
11/20/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

40399/321/NIHD

In re patent application of

Jeffrey RUBIN *et al.*

Serial No. 08/477,983

Group Art Unit: 1646

Filed: June 7, 1995

Examiner: Saoud

For: AN EPITHELIAL CELL
SPECIFIC GROWTH FACTOR
KERATINOCYTE GROWTH
FACTOR (KGF)

SUPPLEMENTAL AMENDMENT AND REQUEST FOR RECONSIDERATION
UNDER 37 C.F.R. § 1.129

Assistant Commissioner of Patents

Washington, D.C. 20231

Sir:

This is in further response to the final rejection of August 5, 1997 and supplements the filing under § 1.129 of August 28, 1998. Applicants do not believe that any petition for extension of time or further fees are currently due. In the event this is not correct, the Commissioner is hereby authorized to debit the undersigned's charge account No. 19-0741. Please amend the application, as follows:

IN THE ORIGINAL SPECIFICATION

At page 103, line 13, please delete "BamH1/BcII fragment containing the majority" and insert -647 bp EcoRI fragment from the 5' end— *N/E*

IN THE CLAIMS

Please cancel claims 13-44, 23-24, 29, 36-37, 39 and 40-43, without prejudice or disclaimer and add the following new claims: